$PBIO has a Perfect Chart w/ Millions in Revenue, Low Float &...
$PBIO has a Perfect Chart w/ Millions in Revenue, Low Float & Insider Buying:
=====================
PBIO (Pressure BioSciences Inc.)
Current Price: $2.19
Float: 1.65M
Chart Analysis
Investor Presentation
========================
Members,
We hope you enjoyed the up to +56% in intraday gains that today's trade idea provided.
If you liked today's trade action, you are going to love what we have in store for you next.
Please turn your immediate attention to PBIO (Pressure BioSciences Inc.).
Just like our most recent winner, this leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, trades on the OTCQB, and has tight float of less than 2M.
PBIO traded nicely today, closing the session up nearly three percent.
We feel confident that this bullish momentum will continue onto tomorrow, as it appears that an uptrend is beginning to take shape.
PBIO has also been getting plenty of positive press as of late.
The Company’s President and CEO, Mr. Richard T. Schumacher, recently joined Stock Day’s Mr. Everett Jolly to discuss the Company's recent successes.
During the interview Mr. Schumacher discussed PBIO's most recent achievements, all of which could be considered bullish catalysts in the immediate future:
Their recent collaboration With NutraFuels, Inc.,
The Commercial Launch of Their BioPharmaceuticals Contract Services Business.
The Publication of More Than Twenty Scientific Papers on the Company’s Unique Pressure-Based Products During 2018.
On top of this, we also noticed some insider buying from PBIO's management in late December.
This leads us to believe that PBIO's management considers the Company's stock price to be undervalued at the moment.
PBIO also looks like a clear cut winner from a technical standpoint as well.
We've done our own chart analysis, and we have to admit, we haven't seen a chart this pretty in quite some time.
This appears to be a bottom-chart play, sitting on a golden pocket, with the potential to more than double in price.
It looks like we have another big mover on our hands here with PBIO.
That being said, we are urging all members to read our full profile, start their research now, and consider grabbing up a position in PBIO tomorrow morning at 9:30AM EST!
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Their products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Their primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of their pressure-based technologies in the following areas: (1) the use of their recently acquired technology from BaroFold, Inc. (the "Barofold" technology) to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of their recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Investment Highlights
Seasoned Management Team & Board of Directors
Annual Revenue of $2.24M (FY2017)
Three Novel, Enabling, Patent Protected, Proprietary Pressure-based Platforms
Proven Core Technology (Over 300 PCT Systems Installed): Razor/Razorblade Business Model
Sales into the Research Market (fast market penetration with minimal approvals required)
Increasing Number of 3rd Party Publications from Marquee Laboratories
PCT Breaks Through Bottlenecks and Barriers to Enable and Accelerate Scientific Discovery
PreEMT Can Impact and Improve Protein Drug Therapeutics
UST Offers the Potential to Produce Highly Stable Nanoemulsions, Including in the Food and CBD Markets
Significant Multi-Billion Dollar Market Opportunity (~500K Scientists in 80K Labs Worldwide)
Company Overview
Three Business Segments - Three Unique Technology Platforms
Research Products and Services (PCT Platform)
PCT: Pressure Cycling Technology (alternating cycles of high/low pressure to control biomolecules)
Focus: to improve the quality of biological sample preparation, one of the most crucial yet errorprone steps in all of scientific research, performed by tens of thousands of scientists worldwide in pharma, biotech, academia and government research laboratories.
15 Patents, 300 PCT Systems installed, 175+ customers, 120+ publications, 2017 revenue ($2.24M)
Biological Contract Services (PreEMT Platform)
PreEMT: Pressure Enabled Protein Manufacturing Technology
Focus: to improve the quality of protein therapeutics, accelerate therapeutic protein development, and manufacture follow-on biologics by employing high pressure for disaggregation & controlled refolding of recombinant proteins into their native structures for desired drug activity.
8 Patents, Dec 2017 BaroFold Acquisition, Initial Contract Underway, Negotiating with Client #2
Nanoemulsion Manufacturing Services (UST Platform)
UST: Ultra Shear Technology (combines high hydrostatic pressure & intense shear forces)
Focus: to produce higher quality, more stable nanoemulsions with improved absorption, higher bioavailability, and lower surfactant levels: food, pharmaceuticals, nutraceuticals, cosmetics, lubricants, paint, and cannabis oil extracts (water soluble CBD) compared to standard emulsions
Short-Term Growth Drivers
Research Products & Services PCT Platform):
New Next Generation Barocycler 2320EXTREME
Additions to Sales & Marketing Team (one to four field sales managers in 2018)
Novel Micro-Pestle Consumable…Potential Use in Pathology, etc.
Four Additional PCT-based Instruments to be Released over Next 12 Months
PBI Products Fill Existing Needs in $291B (2021 est.) Biopharmaceutical Market
Biological Contract Services (PreEMT Platform): Consistent Revenue Stream fromServices to Protein Therapeutic Companies…plus the Potential for Millions of dollars from Royalties on Manufacturing Scale Licenses
Nanoemulsion Manufacturing Services (UST Platform): Consistent Revenue Stream from Services to Food, Cosmetic, and Nutraceutical (CBD, CBG) Markets for Potential Development of Low Cost, Scalable Production of Nanoemulsions…plus the Potential for Millions of dollars from Royalties on Manufacturing Scale Licenses
Recent Developments
In late January PBIO announced news of a collaboration with NutraFuels Inc., to advance the development of a new generation of health and wellness nutraceutical products based on processing by PBI's proprietary Ultra Shear Technology (UST™) platform. The Companies believe that nanoemulsions prepared by the UST Platform will have improved quality and effectiveness compared to current emulsions, which will help to facilitate the development of a new generation of improved nutraceutical and other emulsion-based products, such as cosmetics.
Edgar J. Ward, President and CEO of NTFU, said: "We pride ourselves in ensuring that we incorporate the highest level of quality possible in our manufactured products. When we heard that PBI was developing their new, proprietary UST processing platform, and learned of its potential to significantly increase the quality and effectiveness of nutraceutical products, we spoke with PBI and offered to help accelerate its commercial introduction. We are thrilled to be working with such experienced scientific leaders and innovators, in a program that we believe can change lives worldwide for the better."
Mr. Ward continued: "We believe PBI's UST platform has the potential to create long-term room temperature stable, water-soluble nanoemulsions of oil-based solutions. Nanoemulsions are known to offer greater stability and bioavailability than the standard macroemulsions used today in nutraceuticals, cosmetics, and other industries. We are excited to have the opportunity to work with a life science industry leader in the optimization of a process that has the potential to bring higher quality not just to our products, but to nutraceutical products worldwide."
Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: "We are pleased to have the opportunity to work with NTFU's scientists and manufacturing personnel in the development of new and improved nutraceutical products utilizing our UST platform. This proprietary technology employs ultra-high pressure and extreme shearing forces to create nano-scale emulsions of oil and water with long-term stability. For many oil-based products, the ability to create very small, nanometer-sized oil droplets that can effectively dissolve in water (nanoemulsions) can improve a product's appearance, sensory and medicinal benefits. There is a large and growing market opportunity for nutraceutical products with proven health and wellness benefits. We believe PBI's UST platform can help manufacturers accelerate growth and success in this market with higher quality, water-soluble, oil-based products with superior dietary absorption and shelf-life."
Mr. Richard T. Schumacher, President and CEO of PBI, added: "We are excited to work with Edgar and his NTFU team in the optimization of our UST platform, which we believe will result in the development of new and beneficial health and wellness products. The staff at NTFU has years of experience in manufacturing nutraceutical products in a quality environment. They also have access to both raw materials and finished goods, both of which are needed for optimization. Finally, they have an existing analytical laboratory with state-of-the-art equipment and well-trained chemists who can perform testing on both pre and post-processed materials, which will be invaluable to the optimization process. This collaboration clearly supports both company's strategic objectives: we look forward to an exciting and mutually beneficial relationship with our colleagues at NutraFuels."
Last month, PBIO announced the commercial launch of its Biopharmaceuticals Contract Services Business. The launch of this new business has been eagerly anticipated following the Company's acquisition of the assets of BaroFold, Inc. in December 2017, including patents, equipment, and other intellectual property relating to Barofold's unique, high pressure-based protein disaggregation and refolding platform.
PBI expects that the unique Barofold technology platform will substantially improve the quality and costs of manufacturing protein therapeutics, by helping to resolve protein aggregation, improving solubility, and refolding complex misfolded protein therapeutic molecules into their desired, therapeutically-optimized conformations for improved drug efficacy and lower immunogenicity.
Protein-based therapeutic drugs are a large and rapidly growing part of the global healthcare industry. There are over 200 therapeutic proteins and peptides approved for clinical use in the U.S. (THPdb database: crdd.osdd.net/raghava/thpdb/). Protein therapeutics are valued for their more potent and specific therapeutic effectiveness for many diseases, such as cancer and auto-immune disorders. They are also the preferred treatment choices for hormone and growth factor deficiencies. Research and Markets (May 2016) forecasted that the global protein drug market will grow to $248 billion by 2020.
Market Outlook
Proprietary Technology Platform Offers Improved Manufacturing for Protein Therapeutic Candidates and Positions PBIO to Service the $250 Billion Global Biopharmaceuticals Market
The United States remains the largest medical device market in the world, with a market size of around $156 billion, and it represented about 40 percent of the global medical device market in 2017. U.S. exports of medical devices in key product categories identified by the Department of Commerce (DOC) exceeded $41 billion in that year. The medical technology industry (commonly referred to as medical devices) consists of articles, instruments, apparatuses, or machines that are used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting, or modifying the structure or function of the body for some health purpose. Typically, the purpose of a medical device is not achieved by pharmacological, immunological, or metabolic means.
The industry is responsible for almost 2 million jobs in the United States, including both direct and indirect employment. Medical technology directly accounts for well over 500,000 of these jobs. More than 80 percent of medical device companies in the United States consist of fewer than 50 employees, and many (notably start-up companies) have little or no sales revenue. The medical technology industry employs people in all 50 states. U.S. medical device companies are highly regarded globally for their innovative and high technology products. R&D spending continues to represent a high percentage of medical device industry expenditures, averaging 7 percent of revenue. Compared to several other industries including automotive, defense, and telecommunications, the medical device industry invests a higher percentage of yearly revenues into product innovation, reflecting the competitive nature of the industry and constant innovation and improvement of existing technologies.
The medical device industry relies on several industries where the United States holds a competitive advantage, including microelectronics, telecommunications, instrumentation, biotechnology, and software development. Collaborations have led to recent advances including neuro-stimulators, stent technologies, biomarkers, robotic assistance, and implantable electronic devices. Since innovation fuels the medical device sector’s ongoing quest for better ways to treat and diagnose medical conditions, when coupled with patient life expectancy increasing and aging populations globally, the medical device sector should continue growing at a positive rate in the future.
Technical Analysis
AS we stated above, PBIO appears to be a clear cut winner from a technical standpoint as well.
We've done our own chart analysis, and we have to admit, we haven't seen a chart this pretty in quite some time.
This appears to be a bottom-chart play, sitting on a golden pocket, with the potential to more than double in price.
PBIO has plenty of room to run from here.
The Company is currently down fifty-six percent from its 52-week high of $5.00.
A run back to that high would show traders over +128% in pure profit from today's alert price.
Let's also not forget that the float for PBIO is ridiculously thin at just 1.65M.
With a float that tight, PBIO has the potential to break out for significant gains should it see a sudden burst in trade volume.
If any market friendly news were to be released, we could see shares of PBIO sky-rocket!
We are urging all members to start their research now, and consider grabbing up a position in PBIO tomorrow morning at 9:30AM EST!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by the Financial Marketing Group to conduct investor relations advertising and marketing for PBIO. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
=====================
PBIO (Pressure BioSciences Inc.)
Current Price: $2.19
Float: 1.65M
Chart Analysis
Investor Presentation
========================
Members,
We hope you enjoyed the up to +56% in intraday gains that today's trade idea provided.
If you liked today's trade action, you are going to love what we have in store for you next.
Please turn your immediate attention to PBIO (Pressure BioSciences Inc.).
Just like our most recent winner, this leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, trades on the OTCQB, and has tight float of less than 2M.
PBIO traded nicely today, closing the session up nearly three percent.
We feel confident that this bullish momentum will continue onto tomorrow, as it appears that an uptrend is beginning to take shape.
PBIO has also been getting plenty of positive press as of late.
The Company’s President and CEO, Mr. Richard T. Schumacher, recently joined Stock Day’s Mr. Everett Jolly to discuss the Company's recent successes.
During the interview Mr. Schumacher discussed PBIO's most recent achievements, all of which could be considered bullish catalysts in the immediate future:
Their recent collaboration With NutraFuels, Inc.,
The Commercial Launch of Their BioPharmaceuticals Contract Services Business.
The Publication of More Than Twenty Scientific Papers on the Company’s Unique Pressure-Based Products During 2018.
On top of this, we also noticed some insider buying from PBIO's management in late December.
This leads us to believe that PBIO's management considers the Company's stock price to be undervalued at the moment.
PBIO also looks like a clear cut winner from a technical standpoint as well.
We've done our own chart analysis, and we have to admit, we haven't seen a chart this pretty in quite some time.
This appears to be a bottom-chart play, sitting on a golden pocket, with the potential to more than double in price.
It looks like we have another big mover on our hands here with PBIO.
That being said, we are urging all members to read our full profile, start their research now, and consider grabbing up a position in PBIO tomorrow morning at 9:30AM EST!
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Their products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Their primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of their pressure-based technologies in the following areas: (1) the use of their recently acquired technology from BaroFold, Inc. (the "Barofold" technology) to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of their recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Investment Highlights
Seasoned Management Team & Board of Directors
Annual Revenue of $2.24M (FY2017)
Three Novel, Enabling, Patent Protected, Proprietary Pressure-based Platforms
Proven Core Technology (Over 300 PCT Systems Installed): Razor/Razorblade Business Model
Sales into the Research Market (fast market penetration with minimal approvals required)
Increasing Number of 3rd Party Publications from Marquee Laboratories
PCT Breaks Through Bottlenecks and Barriers to Enable and Accelerate Scientific Discovery
PreEMT Can Impact and Improve Protein Drug Therapeutics
UST Offers the Potential to Produce Highly Stable Nanoemulsions, Including in the Food and CBD Markets
Significant Multi-Billion Dollar Market Opportunity (~500K Scientists in 80K Labs Worldwide)
Company Overview
Three Business Segments - Three Unique Technology Platforms
Research Products and Services (PCT Platform)
PCT: Pressure Cycling Technology (alternating cycles of high/low pressure to control biomolecules)
Focus: to improve the quality of biological sample preparation, one of the most crucial yet errorprone steps in all of scientific research, performed by tens of thousands of scientists worldwide in pharma, biotech, academia and government research laboratories.
15 Patents, 300 PCT Systems installed, 175+ customers, 120+ publications, 2017 revenue ($2.24M)
Biological Contract Services (PreEMT Platform)
PreEMT: Pressure Enabled Protein Manufacturing Technology
Focus: to improve the quality of protein therapeutics, accelerate therapeutic protein development, and manufacture follow-on biologics by employing high pressure for disaggregation & controlled refolding of recombinant proteins into their native structures for desired drug activity.
8 Patents, Dec 2017 BaroFold Acquisition, Initial Contract Underway, Negotiating with Client #2
Nanoemulsion Manufacturing Services (UST Platform)
UST: Ultra Shear Technology (combines high hydrostatic pressure & intense shear forces)
Focus: to produce higher quality, more stable nanoemulsions with improved absorption, higher bioavailability, and lower surfactant levels: food, pharmaceuticals, nutraceuticals, cosmetics, lubricants, paint, and cannabis oil extracts (water soluble CBD) compared to standard emulsions
Short-Term Growth Drivers
Research Products & Services PCT Platform):
New Next Generation Barocycler 2320EXTREME
Additions to Sales & Marketing Team (one to four field sales managers in 2018)
Novel Micro-Pestle Consumable…Potential Use in Pathology, etc.
Four Additional PCT-based Instruments to be Released over Next 12 Months
PBI Products Fill Existing Needs in $291B (2021 est.) Biopharmaceutical Market
Biological Contract Services (PreEMT Platform): Consistent Revenue Stream fromServices to Protein Therapeutic Companies…plus the Potential for Millions of dollars from Royalties on Manufacturing Scale Licenses
Nanoemulsion Manufacturing Services (UST Platform): Consistent Revenue Stream from Services to Food, Cosmetic, and Nutraceutical (CBD, CBG) Markets for Potential Development of Low Cost, Scalable Production of Nanoemulsions…plus the Potential for Millions of dollars from Royalties on Manufacturing Scale Licenses
Recent Developments
In late January PBIO announced news of a collaboration with NutraFuels Inc., to advance the development of a new generation of health and wellness nutraceutical products based on processing by PBI's proprietary Ultra Shear Technology (UST™) platform. The Companies believe that nanoemulsions prepared by the UST Platform will have improved quality and effectiveness compared to current emulsions, which will help to facilitate the development of a new generation of improved nutraceutical and other emulsion-based products, such as cosmetics.
Edgar J. Ward, President and CEO of NTFU, said: "We pride ourselves in ensuring that we incorporate the highest level of quality possible in our manufactured products. When we heard that PBI was developing their new, proprietary UST processing platform, and learned of its potential to significantly increase the quality and effectiveness of nutraceutical products, we spoke with PBI and offered to help accelerate its commercial introduction. We are thrilled to be working with such experienced scientific leaders and innovators, in a program that we believe can change lives worldwide for the better."
Mr. Ward continued: "We believe PBI's UST platform has the potential to create long-term room temperature stable, water-soluble nanoemulsions of oil-based solutions. Nanoemulsions are known to offer greater stability and bioavailability than the standard macroemulsions used today in nutraceuticals, cosmetics, and other industries. We are excited to have the opportunity to work with a life science industry leader in the optimization of a process that has the potential to bring higher quality not just to our products, but to nutraceutical products worldwide."
Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: "We are pleased to have the opportunity to work with NTFU's scientists and manufacturing personnel in the development of new and improved nutraceutical products utilizing our UST platform. This proprietary technology employs ultra-high pressure and extreme shearing forces to create nano-scale emulsions of oil and water with long-term stability. For many oil-based products, the ability to create very small, nanometer-sized oil droplets that can effectively dissolve in water (nanoemulsions) can improve a product's appearance, sensory and medicinal benefits. There is a large and growing market opportunity for nutraceutical products with proven health and wellness benefits. We believe PBI's UST platform can help manufacturers accelerate growth and success in this market with higher quality, water-soluble, oil-based products with superior dietary absorption and shelf-life."
Mr. Richard T. Schumacher, President and CEO of PBI, added: "We are excited to work with Edgar and his NTFU team in the optimization of our UST platform, which we believe will result in the development of new and beneficial health and wellness products. The staff at NTFU has years of experience in manufacturing nutraceutical products in a quality environment. They also have access to both raw materials and finished goods, both of which are needed for optimization. Finally, they have an existing analytical laboratory with state-of-the-art equipment and well-trained chemists who can perform testing on both pre and post-processed materials, which will be invaluable to the optimization process. This collaboration clearly supports both company's strategic objectives: we look forward to an exciting and mutually beneficial relationship with our colleagues at NutraFuels."
Last month, PBIO announced the commercial launch of its Biopharmaceuticals Contract Services Business. The launch of this new business has been eagerly anticipated following the Company's acquisition of the assets of BaroFold, Inc. in December 2017, including patents, equipment, and other intellectual property relating to Barofold's unique, high pressure-based protein disaggregation and refolding platform.
PBI expects that the unique Barofold technology platform will substantially improve the quality and costs of manufacturing protein therapeutics, by helping to resolve protein aggregation, improving solubility, and refolding complex misfolded protein therapeutic molecules into their desired, therapeutically-optimized conformations for improved drug efficacy and lower immunogenicity.
Protein-based therapeutic drugs are a large and rapidly growing part of the global healthcare industry. There are over 200 therapeutic proteins and peptides approved for clinical use in the U.S. (THPdb database: crdd.osdd.net/raghava/thpdb/). Protein therapeutics are valued for their more potent and specific therapeutic effectiveness for many diseases, such as cancer and auto-immune disorders. They are also the preferred treatment choices for hormone and growth factor deficiencies. Research and Markets (May 2016) forecasted that the global protein drug market will grow to $248 billion by 2020.
Market Outlook
Proprietary Technology Platform Offers Improved Manufacturing for Protein Therapeutic Candidates and Positions PBIO to Service the $250 Billion Global Biopharmaceuticals Market
The United States remains the largest medical device market in the world, with a market size of around $156 billion, and it represented about 40 percent of the global medical device market in 2017. U.S. exports of medical devices in key product categories identified by the Department of Commerce (DOC) exceeded $41 billion in that year. The medical technology industry (commonly referred to as medical devices) consists of articles, instruments, apparatuses, or machines that are used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting, or modifying the structure or function of the body for some health purpose. Typically, the purpose of a medical device is not achieved by pharmacological, immunological, or metabolic means.
The industry is responsible for almost 2 million jobs in the United States, including both direct and indirect employment. Medical technology directly accounts for well over 500,000 of these jobs. More than 80 percent of medical device companies in the United States consist of fewer than 50 employees, and many (notably start-up companies) have little or no sales revenue. The medical technology industry employs people in all 50 states. U.S. medical device companies are highly regarded globally for their innovative and high technology products. R&D spending continues to represent a high percentage of medical device industry expenditures, averaging 7 percent of revenue. Compared to several other industries including automotive, defense, and telecommunications, the medical device industry invests a higher percentage of yearly revenues into product innovation, reflecting the competitive nature of the industry and constant innovation and improvement of existing technologies.
The medical device industry relies on several industries where the United States holds a competitive advantage, including microelectronics, telecommunications, instrumentation, biotechnology, and software development. Collaborations have led to recent advances including neuro-stimulators, stent technologies, biomarkers, robotic assistance, and implantable electronic devices. Since innovation fuels the medical device sector’s ongoing quest for better ways to treat and diagnose medical conditions, when coupled with patient life expectancy increasing and aging populations globally, the medical device sector should continue growing at a positive rate in the future.
Technical Analysis
AS we stated above, PBIO appears to be a clear cut winner from a technical standpoint as well.
We've done our own chart analysis, and we have to admit, we haven't seen a chart this pretty in quite some time.
This appears to be a bottom-chart play, sitting on a golden pocket, with the potential to more than double in price.
PBIO has plenty of room to run from here.
The Company is currently down fifty-six percent from its 52-week high of $5.00.
A run back to that high would show traders over +128% in pure profit from today's alert price.
Let's also not forget that the float for PBIO is ridiculously thin at just 1.65M.
With a float that tight, PBIO has the potential to break out for significant gains should it see a sudden burst in trade volume.
If any market friendly news were to be released, we could see shares of PBIO sky-rocket!
We are urging all members to start their research now, and consider grabbing up a position in PBIO tomorrow morning at 9:30AM EST!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by the Financial Marketing Group to conduct investor relations advertising and marketing for PBIO. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.